# Debiopharm International SA clinical trials: 51 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 51 trials with Debiopharm International SA as lead sponsor, 6 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Debiopharm International SA: 51 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/debiopharm-international-sa

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 51
- Recruiting or not yet: 6
- Read on: November 19, 2026

## Trials

The 25 newest of 51, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 11, 2026 | NCT07758608 | Renal Impairment Pharmacokinetics (PK) Trial of Afabicin | Debiopharm International SA | Phase 1 | Recruiting | Renal Impairment | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07758608) |
| June 25, 2025 | NCT07035769 | A First-in-Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of Debio 1453P in Healthy... | Debiopharm International SA | Phase 1 | Recruiting | Healthy Participants | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07035769) |
| May 13, 2025 | NCT06969430 | A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML) | Debiopharm International SA | Phase 1/2 | Recruiting | Acute Myeloid Leukemia | 154 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06969430) |
| April 16, 2025 | NCT06930625 | A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs | Debiopharm International SA | Phase 3 | Recruiting | Acromegaly | 119 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06930625) |
| May 2, 2024 | NCT06395753 | A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer | Debiopharm International SA | Phase 2 | Completed | Prostate Cancer | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06395753) |
| November 13, 2023 | NCT06129539 | A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Central Precocious Puberty... | Debiopharm International SA | Phase 3 | Active not recruiting | Central Precocious Puberty | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06129539) |
| April 18, 2023 | NCT05815160 | Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed... | Debiopharm International SA | Phase 1 | Terminated | Small Cell Lung Cancer Recurrent | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05815160) |
| March 13, 2023 | NCT05765812 | A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and... | Debiopharm International SA | Phase 1/2 | Recruiting | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05765812) |
| May 6, 2022 | NCT05364944 | A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or... | Debiopharm International SA | Phase 1 | Terminated | Acromegaly, GEP-NET | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05364944) |
| December 7, 2021 | NCT05147350 | Study of RP-6306 With FOLFIRI in Advanced Solid Tumors | Debiopharm International SA | Phase 1 | Terminated | Advanced Solid Tumor | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05147350) |
| December 7, 2021 | NCT05147272 | Study of RP-6306 With Gemcitabine in Advanced Solid Tumors | Debiopharm International SA | Phase 1 | Terminated | Adult Solid Tumor | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05147272) |
| November 5, 2021 | NCT05109975 | A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors | Debiopharm International SA | Phase 1 | Terminated | Advanced Solid Tumors | 93 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05109975) |
| July 15, 2021 | NCT04962724 | A Study to Evaluate the Absorption, Metabolism, and Excretion and Absolute Bioavailability of Xevinapant in Healthy Male Participants | Debiopharm International SA | Phase 1 | Completed | Healthy Volunteers | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04962724) |
| April 22, 2021 | NCT04855656 | Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors | Debiopharm International SA | Phase 1 | Recruiting | Advanced Solid Tumor | 464 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04855656) |
| October 10, 2019 | NCT04122625 | Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 | Debiopharm International SA | Phase 1/2 | Completed | Solid Tumor | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04122625) |
| May 30, 2019 | NCT03968653 | Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors | Debiopharm International SA | Phase 1 | Terminated | Advanced Solid Tumors | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03968653) |
| February 7, 2019 | NCT03834220 | Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial) | Debiopharm International SA | Phase 2 | Terminated | Solid Tumor | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03834220) |
| October 29, 2018 | NCT03723551 | Study to Assess Safety, Tolerability and Efficacy of Afabicin in The Treatment of Participants With Bone or Joint Infection Due to... | Debiopharm International SA | Phase 2 | Terminated | Bone or Joint Infection | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03723551) |
| September 1, 2017 | NCT03270176 | A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to... | Debiopharm International SA | Phase 1 | Completed | Carcinoma, Non-Small-Cell Lung, Neoplasms | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03270176) |
| July 6, 2017 | NCT03209648 | A Study to Investigate the Effect of Itraconazole on the Pharmacokinetics of Debio 1450 in Healthy Subjects | Debiopharm International SA | Phase 1 | Completed | Healthy Participants | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03209648) |
| April 28, 2016 | NCT02753699 | Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients | Debiopharm International SA | Phase 3 | Completed | Hepatitis C | 723 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02753699) |
| April 1, 2016 | NCT02726438 | Drug Penetration Into Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement Surgery | Debiopharm International SA | Phase 1 | Completed | Bone Diseases, Infectious | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02726438) |
| November 3, 2015 | NCT02595203 | Mass Balance Recovery and Metabolic Profile of 14C Debio 1450 Following Single Oral and Intravenous Doses in Healthy Male Subjects | Debiopharm International SA | Phase 1 | Completed | Healthy | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02595203) |
| October 1, 2015 | NCT02564744 | Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory... | Debiopharm International SA | Phase 2 | Completed | Diffuse Large B-Cell Lymphoma, B-cell Non-Hodgkin's Lymphoma | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02564744) |
| April 27, 2015 | NCT02426918 | Study of Debio 1450 for Bacterial Skin Infections | Debiopharm International SA | Phase 2 | Completed | Bacterial Infections | 330 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02426918) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 24 |
| Phase 1/2 | 3 |
| Phase 2 | 11 |
| Phase 3 | 9 |
| Not applicable | 4 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 29 |
| Terminated | 13 |
| Recruiting | 6 |
| Withdrawn | 2 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hepatitis C | 10 |
| Hepatitis C, Chronic | 7 |
| Bacterial Infections | 3 |
| Prostatic Neoplasms | 3 |
| Neoplasms | 3 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Puberty, Precocious | 2 |
| Lymphoma, Follicular | 2 |
| Lymphoma | 2 |
| Hepatitis | 2 |
| Acromegaly | 2 |
| Liver Diseases | 2 |
| Heart Failure | 2 |
| Kidney Failure, Chronic | 1 |
| Renal Insufficiency | 1 |
| Small Cell Lung Carcinoma | 1 |
| Recurrence | 1 |
| Astrocytoma | 1 |
| Glioblastoma | 1 |
| Squamous Cell Carcinoma of Head and Neck | 1 |
| Bone Diseases, Infectious | 1 |
| Gastro-enteropancreatic neuroendocrine tumor | 1 |
| Hepatic Insufficiency | 1 |
| Leukemia, Myeloid, Acute | 1 |
| Pituitary Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Web hosting companies in the United States](https://specstream.ai/data/businesses/web-hosting-companies/united-states)
- [Energy management companies in the United States](https://specstream.ai/data/businesses/energy-management-companies/united-states)
- [Pediatric surgery practices in the United States](https://specstream.ai/data/businesses/pediatric-surgery-practices/united-states)
- [Ayurveda clinics in the United States](https://specstream.ai/data/businesses/ayurveda-clinics/united-states)
- [Glass companies in the United States](https://specstream.ai/data/businesses/glass-companies/united-states)
- [Restaurant equipment suppliers in the United States](https://specstream.ai/data/businesses/restaurant-equipment-suppliers/united-states)
